Back

Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452

1 September 2019 (17:32 - 17:50)
Organised by:
Congress Presentation Part of: New developments in anti thrombotic drug therapy Antiplatelet Drugs ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Lisa Jennings

MLM Medical Labs, LLC, Memphis (United States of America)

3 More presentations in this session

Presentation thumbnail
State of the Art - Novel targets in anti thrombotic drug development
Professor B. Rocca (Casamassima, IT)
Slides Video
Presentation thumbnail
Novel direct thrombin inhibitor achieves superior antithrombotic effect with lower bleeding risk than heparin or bivalirudin
Assistant Professor C. Koh (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients
Professor R. Storey (Sheffield, GB)
Abstract Slides Video

Access the full session

Session thumbnail
New developments in anti thrombotic drug therapy

The Event

Event poster

ESC Congress 2019

1 September 2019 17:32 CET
You may be interested in
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources